The role of SBRT was retrospectively investigated in cohorts of patients with liver [52] (N = 43) and brain [53] (N = 351) metastases in EGFR-mutated NSCLC, confirming the OS benefit of TKIs and LAT compared to TKI alone (mOS 36.8 vs 21.3 months, p = 0.034 for liver metastasis, and 46 vs 30 vs 25 months for SBRT plus TKI, whole-brain radiotherapy [WBRT] plus TKI and TKI alone, respectively (p < 0.001)). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.